Remove Drug Trials Remove Drugs Remove Marketing
article thumbnail

Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial

Bio Pharma Dive

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

article thumbnail

HCPs sound off on pharma marketing

World of DTC Marketing

We just finished talking to over 200 hundred HCPs about pharma marketing and salespeople to measure any differences since before the pandemic. Attitudes are indeed changing, but one need remains clear: access to data obtained during clinical and ongoing trials. Will they transform their HCP marketing or stick to dated models?

Marketing 218
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Small Pharma stock market launch funds DMT-based depression drug trial

pharmaphorum

DMT is a powerful hallucinogenic drug found in several plants including the South American plant chacruna and when used recreationally is mixed with the ayahuasca plant to make the shamanic brew of the same name. The goal of the trial is for proof of concept of the drug as a wrap-around therapy for Major Depressive Disorder.

article thumbnail

HCP’s use of social media: the good and the not so good

World of DTC Marketing

86% of diagnostic device companies, 65% of pharma marketers, and over half of biotechs use social as a critical part of their marketing mix to reach HCPs. The best approach is to use social media to connect HCPs to clincial information and drug trials. Doximity was flagged for having anti-vaccine information.

Nurses 294
article thumbnail

GSK suffers another R&D setback, axing ulcerative colitis drug trial

pharmaphorum

GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key lung cancer drug last week. The post GSK suffers another R&D setback, axing ulcerative colitis drug trial appeared first on.

article thumbnail

How does HTA for orphan drugs differ across Europe?

pharmaphorum

Rare diseases drugs have always faced challenges when it comes to HTA approvals, even as governments bring in more regulatory policies that make their path through assessment easier. The results show that HTAs for orphan drugs can vary widely across Europe, causing inconsistencies in evidence requirements and recommendations.

Drugs 122
article thumbnail

Leading clinical packaging companies in contract marketing

Pharmaceutical Technology

Unlike commercial pharmaceutical packaging, the primary consideration in clinical trial packaging is protecting the product quality and reliability for research. Finding the best clinical trial packaging services providers.

Packaging 100